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F ew diseases are as dramatic as peripartum car-diomyopathy (PPCM). This rare illness hasbeen described in cultures across the world, is
little understood, and afﬂicts a woman right at the
moment she brings forth life. Several mechanisms of
disease have been proposed, including myocarditis,
inﬂammation and oxidative stress, the interplay of
prolactin, autoimmune processes, fetal chimerism,
and genetics (1). The current incidence varies depend-
ing on the population studied, from 1 in 1,000 live
births in South Africa to 1 per 2,289 to 4,000 in the
United States. In the current literature, some possible
risk factors have emerged: African-American race (2),
pre-eclampsia, gestational hypertension, advanced
maternal age, and multiparity (3). The majority of
women affected have recovery of left ventricular
(LV) function, but a 6% to 10% mortality remains a
real and serious consequence of PPCM (4). Identifying
those at highest risk of morbidity and mortality
remains a challenge. In 1 study, a dilated LV end-
diastolic diameter (LVEDD) >6 cm on the echocardio-
gram at the time of diagnosis portended a lower
chance of recovery (5). Other emerging markers of
prognosis may include biomarkers, delayed enhance-
ment on cardiac magnetic resonance imaging, and
right ventricular dysfunction (6).
Understanding the natural history of PPCM in the
current era of neurohormonal therapy is crucial in
determining the frequency of clinical monitoring and*Editorials published in the Journal of the American College of Cardiology
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assist devices, and orthotopic heart transplantation.In this issue of the Journal, McNamara et al. (7) and
the 30 North American centers of the Peripartum
Cardiomyopathy Network, funded by the National
Heart, Lung, and Blood Institute, report the largest
prospective study to date of PPCM. In this study, 100
women with PPCM were followed for 1 year post-
partum with echocardiography and clinical follow-
up. Mean age was 30  6 years, 30% were black, and
mean LV ejection fraction (EF) was 35  0.10%. Eight
patients were lost to follow-up. At 1 year after diag-
nosis, the mean LVEF improved from 35  0.10% to
53  1%, which is consistent with our current under-
standing of PPCM. The patients were well-managed
medically, with beta-blocker and angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker use
about 80%. Only 1 patient was treated with bromo-
criptine. What is interesting is not that the majority
of patients had an improvement in EF, but rather the
characteristics of those patients who did not. At 1
year, 13% experienced either a persistent cardiomy-
opathy with an LVEF <35% or had a major clinical
event such as death, need for LV assist device sup-
port, or orthotopic heart transplantation. A very
well-executed analysis of the trial data identiﬁed
that self-identiﬁed black race, LVEDD >6 cm, and
an initial EF <30% predicted a lower chance of
improvement on follow-up. In fact, none of the
patients with an LVEDD >6 cm and EF <30% had
recovery of their LV function. It is also important
to point out that the current trial showed no inter-
action on recovery by previously reported risk fac-
tors, such as multiparity, maternal age, blood
pressure, and New York Heart Association class at
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916presentation. Additionally, breast feeding was not
found to have an effect on EF improvement.
Some limitations of this trial deserve mention,
such as a higher rate of hypertension and a later time
of diagnosis of PPCM in black subjects. This could be
interpreted as a signiﬁcant ﬂaw in the analysis of race
and outcomes, or potentially underline hypothesis-
generating racial differences in the pathophysiology
of the condition.
Beyond routine medical therapy for heart failure,
current therapies that have shown promise in the
treatment of PPCM include bromocriptine (8), pen-
toxifylline (9), and intravenous immunoglobulin (10).
None of these studies were deﬁnitive, likely because
in the majority of patients, EF normalizes regardless
of intervention. This prospective cohort is a landmark
trial in PPCM because it may pave the way for futuretreatment studies. Perhaps by enrolling only patients
with an LVEDD >6 cm and/or an EF <30% at diagnosis
will allow for more robust trial results. Hopefully, the
1-year results of the Peripartum Cardiomyopathy
Network cohort will be only the ﬁrst of several ana-
lyses to come. Many questions still need to be
addressed, such as the risk of recurrent heart failure
after additional pregnancies in patients with PPCM.
The multicenter framework of this large cohort will
likely continue to add new insights into this rare and
potentially devastating cardiomyopathy.
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